Oncology

The chief executive officer of Cartherics discussed the company’s development of NK cell, T-cell, and macrophage cell therapies for various solid tumor indications.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Of the 20 mice treated with the experimental approach, 19 achieved clearance of residual tumor cells.

Poolbeg Pharma’s POLB 001 previously showed promise in a lipopolysaccharide human challenge trial.

The associate professor of medicine at Siteman Cancer Center and WUSTL discussed further research to be done with CAR T-cell therapies.

Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, Co-Founder, Executive Vice President, and Chief Medical Officer, CLL Society, discussed the role the society plays in the field.

Review top news and interview highlights from the week ending January 13, 2023.

The chief medical and scientific officer of Tessa Therapeutics discussed data from the BESTA and CHARIOT studies presented at ASH 2022.

The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of B4t2-001.

The assistant member of the bone marrow transplantation and cellular therapy department at St. Jude Children’s Hospital discussed preclinical research presented at ASH 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The clinician scientist at St. Jude Children’s Research Hospital discussed the session on cell therapies in acute leukemias and Hodgkin lymphoma she moderated at ASH 2022.

Instil Bio, ITIL-306’s developer, expects to present initial data from the phase 1 trial’s dose escalation cohorts this year.

The assistant member at St. Jude Children’s Research Hospital discussed the ASH 2022 basic and translational science session she moderated.

huMNC2-CAR22 is designed to avoid off-tissue expression and reduce T-cell exhaustion.

CKO804 is being evaluated as an add-on therapy to ruxolitinib in patients whose disease had a suboptimal response to ruxolitinib alone.

Review top news and interview highlights from the week ending January 6, 2023.

Ying Huang, chief executive officer, Legend Biotech, discussed new data from the CARTIFAN-1 and CARTITUDE-2 studies.

The associate professor of medicine from University of Pennsylvania discussed updated data on huCART19-IL18 presented at the ASH 2022 meeting.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CT103A is currently being evaluated in multiple clinical trials in China.

The assistant member at St. Jude Children’s Research Hospital discussed updated data from a phase 1 study being conducted at the hospital.

The BALLI-01 study, initiated in 2019, has now dosed its first patient with an in-house manufactured CAR T-cell therapy candidate.

The company is seeking out other companies to continue development of its autologous CAR-T platform.

Updated data were presented at the ASH 2022 annual meeting.